Sandoz US and its Fougera Pharmaceuticals subsidiary will pay a total of $265m to direct purchaser plaintiffs in US antitrust litigation over generic pricing, as part of a deal that the generics giant has reached to resolve the matter in exchange for “full release of all claims by the class.”
Sandoz Agrees $265m Settlement To Resolve US Pricing Litigation
Firm Says Purchasers Deal Underscores ‘Commitment To Integrity And Sound Governance’
Sandoz has agreed a $265m settlement in the US to resolve generic pricing antitrust class action litigation with direct purchaser plaintiffs, as part of a deal that contains no admission of wrongdoing on the part of the generics giant.
More from Deals
More from Business
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.